Business Description
ASLAN Pharmaceuticals Ltd
ISIN : US04522R2004
Share Class Description:
STU:7A90: ADRDescription
ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. The Company's major business is research and development and operates only in one single segment.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.69 | |||||
| Equity-to-Asset | -0.86 | |||||
| Debt-to-Equity | -1.48 | |||||
| Debt-to-EBITDA | -0.86 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -26.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -6.1 | |||||
| 3-Year EPS without NRI Growth Rate | -12.4 | |||||
| 3-Year FCF Growth Rate | -13.1 | |||||
| 3-Year Book Growth Rate | 15.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.05 | |||||
| Quick Ratio | 1.05 | |||||
| Cash Ratio | 0.94 | |||||
| Days Sales Outstanding | 365 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -28 | |||||
| Shareholder Yield % | 278.65 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -290.42 | |||||
| Net Margin % | -291.88 | |||||
| FCF Margin % | -386.22 | |||||
| ROA % | -85.11 | |||||
| ROIC % | -335.91 | |||||
| 3-Year ROIIC % | 1363.46 | |||||
| ROC (Joel Greenblatt) % | -3574.41 | |||||
| ROCE % | -148.27 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.1 | |||||
| EV-to-EBIT | -0.32 | |||||
| EV-to-EBITDA | -0.32 | |||||
| EV-to-Revenue | 0.83 | |||||
| EV-to-Forward-Revenue | -128.7 | |||||
| EV-to-FCF | -0.21 | |||||
| Earnings Yield (Greenblatt) % | -312.5 | |||||
| FCF Yield % | -2748.97 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ASLAN Pharmaceuticals Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 11.076 | ||
| EPS (TTM) (€) | -13.777 | ||
| Beta | 0.33 | ||
| Volatility % | 125.48 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 22.8 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 22.8 - 22.8 | ||
| Shares Outstanding (Mil) | 2.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ASLAN Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ASLAN Pharmaceuticals Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
ASLAN Pharmaceuticals Ltd Frequently Asked Questions
What is ASLAN Pharmaceuticals Ltd(STU:7A90)'s stock price today?
The current price of STU:7A90 is €22.80. The 52 week high of STU:7A90 is €22.80 and 52 week low is €22.80.
When is next earnings date of ASLAN Pharmaceuticals Ltd(STU:7A90)?
The next earnings date of ASLAN Pharmaceuticals Ltd(STU:7A90) is 2024-11-12 Est..
Does ASLAN Pharmaceuticals Ltd(STU:7A90) pay dividends? If so, how much?
ASLAN Pharmaceuticals Ltd(STU:7A90) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers